Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Figer

Showing results (101-110 of 110) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 110 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancerA de Gramont, A Figer, M Seymour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2006
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patientsHans-Joachim Schmoll, Thomas Cartwright, Josep Tabernero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2023
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal CancerA de Gramont, A Figer, M Seymour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology GroupRichard Herrmann, György Bodoky, Thomas Ruhstaller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancerAimery de Gramont, Marc Buyse, Jose Cortinas Abrahantes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001Jürg Bernhard, Daniel Dietrich, Werner Scheithauer, et al.
Targeted Oncology|January 22, 2018
Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical ExperienceOfer Purim, Alexander Beny, Moshe Inbar, et al.
British Journal of Cancer|April 20, 2006
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trialJ Cassidy, J-Y Douillard, C Twelves, et al.
American Journal of Human Genetics|November 28, 2002
The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish populationW D Foulkes, I Thiffault, S B Gruber, et al.
Pageof 11

Showing results (101-110 of 110) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 110 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2023
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials GroupMalcolm J Moore, David Goldstein, John Hamm, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancerA de Gramont, A Figer, M Seymour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2006
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patientsHans-Joachim Schmoll, Thomas Cartwright, Josep Tabernero, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 15, 2023
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal CancerA de Gramont, A Figer, M Seymour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology GroupRichard Herrmann, György Bodoky, Thomas Ruhstaller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 2007
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancerAimery de Gramont, Marc Buyse, Jose Cortinas Abrahantes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001Jürg Bernhard, Daniel Dietrich, Werner Scheithauer, et al.
Targeted Oncology|January 22, 2018
Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical ExperienceOfer Purim, Alexander Beny, Moshe Inbar, et al.
British Journal of Cancer|April 20, 2006
Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trialJ Cassidy, J-Y Douillard, C Twelves, et al.
American Journal of Human Genetics|November 28, 2002
The founder mutation MSH2*1906G-->C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish populationW D Foulkes, I Thiffault, S B Gruber, et al.
Pageof 11